Kalaris Therapeutics Inc. (KLRS) vs XBiotech Inc. (XBIT)

Kalaris Therapeutics Inc. and XBiotech Inc. are both Biotechnology companies. Kalaris Therapeutics Inc. and XBiotech Inc. are of similar size ($67.1M and $65.9M). Across the 10 metrics below, XBiotech Inc. leads on 6 and Kalaris Therapeutics Inc. on 4.

Valuation

Metric KLRS XBIT Biotechnology median
P/E n/m n/m 7.88
P/S n/m 16.50 11.47
P/B 1.20 0.52 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA 0.09 0.71 0.74
EV/Sales n/m (8.26) 10.73
Earnings yield (69.18%) (68.20%) (28.84%)
Free cash flow yield (58.83%) (61.95%) (23.03%)

Profitability

Metric KLRS XBIT Biotechnology median
Gross margin 0.00% 0.00% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (79.91%) (29.94%) (57.72%)
Return on assets (46.02%) (28.90%) (49.22%)
Return on invested capital 0.00% (159.18%) 0.00%

Growth

Metric KLRS XBIT Biotechnology median
Revenue growth (TTM) — (78.20%) 5.64%
EPS growth (last fiscal year) 94.50% (18.25%) —
Revenue growth, 5-year CAGR — — 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric KLRS XBIT Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 10.98 33.15 4.73
Net debt to EBITDA 2.54 2.33 0.96

Dividend

Metric KLRS XBIT Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric KLRS XBIT Biotechnology median
Market cap 67.05m 65.85m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack